EMG electrode market seen reaching $1.41 billion by 2030

The electromyography electrode market is projected to grow from $0.98 billion in 2025 to $1.06 billion in 2026, driven by rising neurological disorders and broader diagnostic use. North America led the market in 2025, while demand is expected to keep rising through 2030 as healthcare providers expand neuromuscular testing and rehabilitation care.

Why it matters: - EMG electrodes are core tools for diagnosing neuromuscular disorders and measuring muscle electrical activity. - The market’s growth tracks with rising neurological disease burden, aging populations and greater demand for earlier diagnosis. - The report points to expanding use in rehabilitation and sports medicine, which could widen the customer base beyond hospital diagnostics.

What happened: - The Business Research Company released a 2026 report on the global electromyography (EMG) electrode market. - The market is projected to rise from $0.98 billion in 2025 to $1.06 billion in 2026, a 7.6% CAGR. - The market is forecast to reach $1.41 billion by 2030, growing at a 7.5% CAGR. - North America was the largest regional market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also offered a free sample of the report and the full market report.

The details: - EMG electrodes can be surface electrodes placed on the skin or needle electrodes inserted into muscle. - The devices detect and record electrical activity generated by skeletal muscles. - They support diagnosis, muscle performance evaluation and treatment planning. - Market growth has been driven by rising incidence of neuromuscular disorders, expansion of hospital-based EMG diagnostic services, growth in neurology and rehabilitation departments, increased use of EMG for muscle function evaluation and better access to diagnostic equipment. - The report expects continued demand for disposable EMG electrodes, high-sensitivity and signal-stable electrodes, and surface EMG electrodes. - The report also highlights broader use in neuromuscular disorder diagnostics, rehabilitation and sports medicine. - North America’s lead is tied to advanced healthcare infrastructure, broad access to diagnostic technology and strong investment in neurological and rehabilitative care.

Between the lines: - The report signals a shift from basic diagnostic coverage toward more specialized, higher-volume testing across care settings. - Disposable electrodes and surface EMG products may gain share as clinicians prioritize convenience, hygiene and repeat use in routine workflows. - The strongest regional markets appear to be those with mature diagnostic systems and higher spending on neurological care. - The World Federation of Neurology reported in October 2023 that over 40% of the global population has some form of neurological condition, and that burden is expected to nearly double by 2050. - The same group said stroke-related deaths worldwide could rise 50% to 9.7 million annually by 2050.

What's next: - Demand is expected to keep rising as populations age and healthcare systems expand early diagnosis and rehabilitation services. - Specialized diagnostic centers and higher healthcare spending on neurological and muscular care are likely to support further growth through 2030. - The report expects market expansion to continue as EMG use broadens in clinical and sports settings. - The company says 2026 report upgrades include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspots infographics, key technologies analysis and updated graphics and tables.

The bottom line: - EMG electrodes are moving from a niche diagnostic tool toward broader clinical use, and the market’s growth outlook remains steady through 2030.